Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients

被引:19
作者
Gagelmann, Nico [1 ]
Ayuk, Francis A. [1 ]
Klyuchnikov, Evgeny [1 ]
Wolschke, Christine [1 ]
Berger, Susanna Carolina [1 ]
Kroeger, Nicolaus [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
关键词
CILTACABTAGENE AUTOLEUCEL;
D O I
10.3324/haematol.2022.282510
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:2799 / 2802
页数:4
相关论文
共 17 条
[1]   Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].
Berdeja, Jesus G. ;
Madduri, Deepu ;
Usmani, Saad Z. ;
Jakubowiak, Andrzej ;
Agha, Mounzer ;
Cohen, Adam D. ;
Stewart, A. Keith ;
Hari, Parameswaran ;
Htut, Myo ;
Lesokhin, Alexander ;
Deol, Abhinav ;
Munshi, Nikhil C. ;
O'Donnell, Elizabeth ;
Avigan, David ;
Singh, Indrajeet ;
Zudaire, Enrique ;
Yeh, Tzu-Min ;
Allred, Alicia J. ;
Olyslager, Yunsi ;
Banerjee, Arnob ;
Jackson, Carolyn C. ;
Goldberg, Jenna D. ;
Schecter, Jordan M. ;
Deraedt, William ;
Zhuang, Sen Hong ;
Infante, Jeffrey ;
Geng, Dong ;
Wu, Xiaoling ;
Carrasco-Alfonso, Marlene J. ;
Akram, Muhammad ;
Hossain, Farah ;
Rizvi, Syed ;
Fan, Frank ;
Lin, Yi ;
Martin, Thomas ;
Jagannath, Sundar .
LANCET, 2021, 398 (10297) :314-324
[2]   European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma [J].
Bruno, Benedetto ;
Wasch, Ralph ;
Engelhardt, Monika ;
Gay, Francesca ;
Giaccone, Luisa ;
D'Agostino, Mattia ;
Rodriguez-Lobato, Luis-Gerardo ;
Danhof, Sophia ;
Gagelmann, Nico ;
Kroeger, Nicolaus ;
Popat, Rakesh ;
van de Donk, Niels W. C. J. ;
Terpos, Evangelos ;
Dimopoulos, Meletios A. ;
Sonneveld, Pieter ;
Einsele, Hermann ;
Boccadoro, Mario .
HAEMATOLOGICA, 2021, 106 (08) :2054-2065
[3]  
Gagelmann N, 2022, LANCET HAEMATOL, V9, pE786, DOI 10.1016/S2352-3026(22)00226-5
[4]   Development of CAR-T cell therapies for multiple myeloma [J].
Gagelmann, Nico ;
Riecken, Kristoffer ;
Wolschke, Christine ;
Berger, Carolina ;
Ayuk, Francis A. ;
Fehse, Boris ;
Kroeger, Nicolaus .
LEUKEMIA, 2020, 34 (09) :2317-2332
[5]   B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis [J].
Gagelmann, Nico ;
Ayuk, Francis ;
Atanackovic, Djordje ;
Kroeger, Nicolaus .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) :318-327
[6]   Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors A Systematic Review and Meta-analysis [J].
Giri, Smith ;
Grimshaw, Alyssa ;
Bal, Susan ;
Godby, Kelly ;
Kharel, Prakash ;
Djulbegovic, Benjamin ;
Dimopoulos, Meletios A. ;
Facon, Thierry ;
Usmani, Saad Z. ;
Mateos, Maria-Victoria ;
Costa, Luciano J. .
JAMA ONCOLOGY, 2020, 6 (11) :1759-1765
[7]   Current approaches to management of high-risk multiple myeloma [J].
Goldman-Mazur, Sarah ;
Kumar, Shaji K. .
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) :854-871
[8]   GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias) [J].
Guyatt, Gordon H. ;
Oxman, Andrew D. ;
Vist, Gunn ;
Kunz, Regina ;
Brozek, Jan ;
Alonso-Coello, Pablo ;
Montori, Victor ;
Akl, Elie A. ;
Djulbegovic, Ben ;
Falck-Ytter, Yngve ;
Norris, Susan L. ;
Williams, John W., Jr. ;
Atkins, David ;
Meerpohl, Joerg ;
Schuenemann, Holger J. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :407-415
[9]   The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J].
Higgins, Julian P. T. ;
Altman, Douglas G. ;
Gotzsche, Peter C. ;
Jueni, Peter ;
Moher, David ;
Oxman, Andrew D. ;
Savovic, Jelena ;
Schulz, Kenneth F. ;
Weeks, Laura ;
Sterne, Jonathan A. C. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
[10]  
Hillengass J, 2022, CL LYMPH MYELOM LEUK, V22, pS411, DOI 10.1016/S2152-2650(22)01600-7